CA2360668C - The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation - Google Patents

The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation Download PDF

Info

Publication number
CA2360668C
CA2360668C CA002360668A CA2360668A CA2360668C CA 2360668 C CA2360668 C CA 2360668C CA 002360668 A CA002360668 A CA 002360668A CA 2360668 A CA2360668 A CA 2360668A CA 2360668 C CA2360668 C CA 2360668C
Authority
CA
Canada
Prior art keywords
alkyl
flavopiridol
alkylamino
dosage
smc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002360668A
Other languages
English (en)
French (fr)
Other versions
CA2360668A1 (en
Inventor
Winston Campbell Patterson
Jennifer A. Dumont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
University of Texas System
Original Assignee
Aventis Pharmaceuticals Inc
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc, University of Texas System filed Critical Aventis Pharmaceuticals Inc
Publication of CA2360668A1 publication Critical patent/CA2360668A1/en
Application granted granted Critical
Publication of CA2360668C publication Critical patent/CA2360668C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002360668A 1999-02-01 2000-01-18 The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation Expired - Fee Related CA2360668C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24338099A 1999-02-01 1999-02-01
US09/243,380 1999-02-01
US09/468,665 1999-12-21
US09/468,665 US6399633B1 (en) 1999-02-01 1999-12-21 Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
PCT/US2000/001104 WO2000044362A2 (en) 1999-02-01 2000-01-18 The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation

Publications (2)

Publication Number Publication Date
CA2360668A1 CA2360668A1 (en) 2000-08-03
CA2360668C true CA2360668C (en) 2009-03-17

Family

ID=22918541

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002360668A Expired - Fee Related CA2360668C (en) 1999-02-01 2000-01-18 The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation

Country Status (38)

Country Link
US (1) US6399633B1 (https=)
EP (1) EP1150746B1 (https=)
JP (1) JP4755759B2 (https=)
KR (1) KR100793047B1 (https=)
CN (1) CN1219556C (https=)
AP (1) AP1469A (https=)
AR (1) AR042569A1 (https=)
AT (1) ATE275428T1 (https=)
AU (1) AU777368B2 (https=)
BG (1) BG65151B1 (https=)
BR (1) BR0007911A (https=)
CA (1) CA2360668C (https=)
CR (1) CR6448A (https=)
CZ (1) CZ300395B6 (https=)
DE (1) DE60013555T2 (https=)
DK (1) DK1150746T3 (https=)
EA (1) EA004786B1 (https=)
EE (1) EE04851B1 (https=)
ES (1) ES2226792T3 (https=)
HK (1) HK1042445B (https=)
HR (1) HRP20010521A2 (https=)
HU (1) HU229263B1 (https=)
ID (1) ID30180A (https=)
IL (1) IL144668A (https=)
ME (1) MEP10508A (https=)
NO (1) NO330512B1 (https=)
NZ (1) NZ512822A (https=)
OA (1) OA11755A (https=)
PL (1) PL197693B1 (https=)
PT (1) PT1150746E (https=)
RS (1) RS50242B (https=)
SI (1) SI1150746T1 (https=)
SK (1) SK286747B6 (https=)
TR (1) TR200102223T2 (https=)
TW (1) TWI273907B (https=)
UA (1) UA73110C2 (https=)
WO (1) WO2000044362A2 (https=)
ZA (1) ZA200105596B (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102480D0 (en) * 2001-01-31 2001-03-14 Cyclacel Ltd Marker
NZ536190A (en) * 2002-04-17 2007-08-31 Cytokinetics Inc Compounds for treating cellular proliferative diseases by modulating the activity of the mitotic kinesin KSP
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040082613A1 (en) * 2002-06-28 2004-04-29 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
US20040106647A1 (en) * 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
WO2004022097A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
CA2602035C (en) 2005-03-18 2015-06-16 Medimmune, Inc. Framework-shuffling of antibodies
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
WO2007010342A1 (en) * 2005-07-15 2007-01-25 Sahajanand Biotech Private Limited Implantable medical devices comprising a flavonoid or derivative thereof for prevention of restenosis
JP2008255008A (ja) * 2005-07-19 2008-10-23 Tokyo Medical & Dental Univ 滑膜細胞増殖抑制剤
US8410109B2 (en) * 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
AU2007290570C1 (en) 2006-08-28 2013-08-15 Kyowa Kirin Co., Ltd. Antagonistic human LIGHT-specific human monoclonal antibodies
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
CA2682292A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
SI2346837T1 (sl) 2008-06-26 2015-05-29 Resverlogix Corporation Postopki pripravljanja kinazolinonskih derivatov
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
WO2012007327A1 (en) 2010-07-12 2012-01-19 Dkfz Deutsches Krebsforschungszentrum Wogonin for the prevention and therapy of cardiac hypertrophy
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
SG11201509982UA (https=) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
AU2014332442B2 (en) 2013-08-26 2019-12-19 Biontech Research And Development, Inc. Nucleic acids encoding human antibodies to Sialyl-Lewis
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9856324B2 (en) 2014-06-04 2018-01-02 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside GD2
JP6800853B2 (ja) 2014-12-11 2020-12-16 ピエール、ファーブル、メディカマン 抗ｃ１０ｏｒｆ５４抗体およびその使用
KR20250005465A (ko) 2015-03-03 2025-01-09 키맵 리미티드 항체, 용도 및 방법
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
HK1251655A1 (zh) 2015-04-20 2019-02-01 Tolero Pharmaceuticals, Inc. 通过线粒体分析预测对阿伏西地的应答
KR102608921B1 (ko) 2015-05-18 2023-12-01 스미토모 파마 온콜로지, 인크. 생체 이용률이 증가된 알보시딥 프로드러그
JP7083497B2 (ja) 2015-08-03 2022-06-13 スミトモ ファーマ オンコロジー， インコーポレイテッド がんの処置のための併用療法
EP3383908A1 (en) 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
EP3383911B1 (en) 2015-12-02 2021-01-20 STCube & Co. Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
BR112019003722A2 (pt) 2016-08-23 2019-05-28 Eisai R&D Man Co Ltd terapias de combinação para o tratamento de carcinoma hepatocelular
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
MX2019010981A (es) 2017-03-16 2020-09-07 Eisai R&D Man Co Ltd Terapias de combinacion para el tratamiento de cancer de mama.
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
KR20200026209A (ko) 2017-06-06 2020-03-10 주식회사 에스티큐브앤컴퍼니 Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
CN113559244B (zh) * 2021-08-02 2023-12-26 华中科技大学同济医学院附属协和医院 Ctrp13脂肪因子的新用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (https=) * 1986-04-11 1989-02-04 Hoechst India
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
US5908934A (en) 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs
WO1998033798A2 (en) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation

Also Published As

Publication number Publication date
AP1469A (en) 2005-09-26
EP1150746B1 (en) 2004-09-08
TWI273907B (en) 2007-02-21
BR0007911A (pt) 2001-10-16
ES2226792T3 (es) 2005-04-01
BG65151B1 (bg) 2007-04-30
DE60013555D1 (de) 2004-10-14
KR100793047B1 (ko) 2008-01-10
KR20010093309A (ko) 2001-10-27
NO20013335D0 (no) 2001-07-05
EA200100742A1 (ru) 2001-12-24
EA004786B1 (ru) 2004-08-26
YU54401A (sh) 2004-05-12
BG105751A (en) 2002-02-28
PT1150746E (pt) 2004-12-31
HUP0200804A2 (hu) 2002-12-28
ZA200105596B (en) 2002-10-07
AU777368B2 (en) 2004-10-14
TR200102223T2 (tr) 2004-12-21
MEP10508A (en) 2010-06-10
RS50242B (sr) 2009-07-15
PL350735A1 (en) 2003-01-27
SK286747B6 (sk) 2009-04-06
DE60013555T2 (de) 2005-09-29
EE04851B1 (et) 2007-06-15
SI1150746T1 (en) 2005-02-28
HK1042445B (zh) 2006-01-13
EP1150746A2 (en) 2001-11-07
UA73110C2 (en) 2005-06-15
CA2360668A1 (en) 2000-08-03
HRP20010521A2 (en) 2002-08-31
US6399633B1 (en) 2002-06-04
OA11755A (en) 2005-07-19
EE200100385A (et) 2002-12-16
JP4755759B2 (ja) 2011-08-24
HU229263B1 (en) 2013-10-28
CZ20012804A3 (cs) 2002-08-14
CN1219556C (zh) 2005-09-21
NO330512B1 (no) 2011-05-09
CR6448A (es) 2004-03-17
JP2002535356A (ja) 2002-10-22
DK1150746T3 (da) 2005-01-10
HUP0200804A3 (en) 2004-03-29
HK1042445A1 (en) 2002-08-16
AP2001002218A0 (en) 2001-09-30
CZ300395B6 (cs) 2009-05-06
SK10862001A3 (sk) 2002-07-02
NZ512822A (en) 2005-01-28
AU3209800A (en) 2000-08-18
AR042569A1 (es) 2005-06-29
ID30180A (id) 2001-11-08
WO2000044362A3 (en) 2001-04-05
WO2000044362A2 (en) 2000-08-03
NO20013335L (no) 2001-09-25
CN1338958A (zh) 2002-03-06
IL144668A (en) 2005-06-19
ATE275428T1 (de) 2004-09-15
PL197693B1 (pl) 2008-04-30
IL144668A0 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
CA2360668C (en) The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
Teresi et al. Increased PTEN expression due to transcriptional activation of PPARγ by Lovastatin and Rosiglitazone
Kwak et al. PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways
Zhu et al. Small GTPase ARF6 controls VEGFR2 trafficking and signaling in diabetic retinopathy
US20040082498A1 (en) Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
EP2889297B1 (en) Activators and therapeutic applications thereof
JP2009521470A (ja) シヌクレイン障害の治療
Zhang et al. Role of cyclin-dependent kinase 2 in the progression of mouse juvenile cystic kidney disease
Kikuchi et al. p27kip1 Antisense-induced proliferative activity of rat corneal endothelial cells
Scaife Selective and irreversible cell cycle inhibition by diphenyleneiodonium
MXPA01007278A (en) The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
US8367678B2 (en) Treatment for spinal muscular atrophy
US6495588B2 (en) Scytonemin and methods of using thereof
US20090054500A1 (en) Composition and methods useful in preventing cardiac hypertrophy

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150119